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Abstract: Different factors have been related with interictal anxiety, reported in 10%–25% of 
patients with epilepsy. We determined the frequency of interictal anxiety in 196 patients with 
active epilepsy in a cross-sectional survey to know which symptoms of anxiety were most 
frequently reported in patients with epilepsy and to analyze the factors associated with their 
presence. Patients were assessed with the Beck Depression Inventory (BDI), Montgomery-
Asberg Depression Rating Scale (MADRS), and the Hamilton Anxiety Scale (HAMA). Data 
were analyzed with a logistic regression model. The HAMA ratings revealed that 38.8% 
experienced signiﬁ  cant anxiety symptoms, as deﬁ  ned by a rating above 18 points. Use of 
primidone, depression, cryptogenic, and posttraumatic etiologies signiﬁ  cantly predicted anxiety 
after logistic regression. Symptoms related to higher scores on HAMA were anxious mood, 
tension, insomnia, intellectual function, depressed mood, cardiovascular and genitourinary 
symptoms. Further studies should be performed to deﬁ  ne the role of psychosocial factors in 
the development and evolution of anxiety among these patients.
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Introduction
Anxiety disorders in epilepsy can be classiﬁ  ed according to the temporal relationship 
with the ictal event. Preictal anxiety precedes the onset of seizures by hours or days 
(Hughes et al 1993). Postictal fear can last up to 7 days after the seizure. In ictal 
anxiety, nervousness, fear, anger and irritability can be a partial seizure or an “aura” of 
a complex partial seizure (Gaitatzis et al 2004); especially among patients with temporal 
lobe epilepsy (TLE) (10%–15% with lateral foci and 15%–20% with medial foci) 
(Gloor et al 1982; Devinsky 2003). Ictal foci on other locations have been related to 
ictal fear (Hermann and Chhabria 1980). Interictal anxiety is deﬁ  ned as the presence of 
anxiety symptoms without temporal relationship with seizures (Hermann and Chhabria 
1980). It can manifest as clinical anxiety disorders such as panic disorder, general 
anxiety disorder, or obsessive compulsive disorder (Nickell and Uhde 1999).
The prevalence of interictal anxiety in epilepsy varies among the type of sample 
studied. Anxiety has been found in 10%–25% of patients with epilepsy in the 
community (Edeh and Toone 1987; Gureje 1991; Jacoby et al 1996); in 19% of TLE 
(Currie et al 1971) and in 24.7% in surgical candidates (Devinsky et al 2005). It is 
more severe among patients with focal epilepsy (Gureje 1991) and more frequent 
compared with normal controls and patients with other chronic diseases (Perini et al 
1996; Kanner 2002; Gaitatzis et al 2004).
The origin and type of seizures (Piazzini et al 2001), the diagnosis of temporal 
lobe epilepsy with amygdala involvement (Reynders et al 2005), the use of 
antiepileptic drugs (McConnell et al 1996; Mula et al 2003), and psychological 
factors (Hermann 1991) have been related to the development of anxiety in 
patients with epilepsy.Neuropsychiatric Disease and Treatment 2008:4(6) 1236
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However, there is less information regarding which 
symptoms are related to seizures and which ones are due to 
anxiety itself.
We performed the present study to determine the 
frequency of anxiety in patients with epilepsy in order to 
discover which symptoms of anxiety were the most fre-
quently reported in patients with epilepsy and to analyze the 
factors associated with its development.
Methods
We conducted a cross-sectional survey in all consecutive 
outpatients with epilepsy, deﬁ  ned as recurrent seizures, 
who attended the National Institute of Neurology of Mexico 
between September 2006 and March 2007. Patients with 
symptomatic epilepsy secondary to brain neoplasms, 
vascular malformations, neurocysticercosis (in all patients 
with diagnosis of mesial temporal sclerosis, one or more 
magnetic resonance imaging (MRI) scans were performed 
to rule out neurocysticercosis), other cerebral infections, 
cerebrovascular disease, or mental retardation, were excluded 
as well as patients with a seizure occurring the day of the 
research interview, or the day before. No patient received 
antidepressants or antipsychotic medication, and no patient 
had a prior diagnosis of anxiety or depression. A structured, 
ad hoc questionnaire was used to register demographical 
and clinical data. We classiﬁ  ed patients in primary general-
ized and partial epilepsy based on the clinical features of 
seizures according to the International League Against Epi-
lepsy Classiﬁ  cation of Epileptic Seizures (Commission on 
Classiﬁ  cation and Terminology of the International League 
Against Epilepsy 1981) and supported by the electroen-
cephalogram (EEG) ﬁ  ndings. Patients that were classiﬁ  ed as 
primary generalized epilepsy had generalized seizures and 
generalized epilpetiform activity; while those patients with 
simple partial, complex-partial and partial-onset secondary 
generalized seizures and/or focal epileptiform activity were 
classiﬁ  ed as having partial epilepsy.
Patients were assessed with the Beck Depression Inven-
tory (BDI) and Montgomery-Asberg Depression Rating 
Scale (MADRS), and were classiﬁ  ed as having a depres-
sive syndrome when both scales indicated so by means of 
standard cut-off points (14 points in the BDI and 20 points 
in the MADRS).
The Hamilton Anxiety Scale (HAMA) was assessed 
by a clinical neuropsychiatrist. Patients were classiﬁ  ed as 
having an anxiety syndrome when the scale indicated so by 
means of a standard cut-off point (18 points). The diagnosis 
of generalized anxiety disorder was conﬁ  rmed according to 
DSM-IV criteria using a semistructured interview performed 
by a neuropsychiatrist.
A consent form was obtained for all cases, signed by 
the patient and two family members, as required by the 
institutional Ethics Committee.
The data analysis was performed with the SPSS version 
10 (SPSS Inc., Chicago, IL) program, including descriptive 
statistics, normality tests, and a bivariate analysis with the 
use of Pearson’s chi-square tests, Mann Whitney tests, and 
t-tests. A logistic regression model was constructed taking 
anxiety syndrome as dependent variable and all variables 
signiﬁ  cant in the previous bivariate analysis as independent 
ones (p  0.05) in order to control for possible confounding 
variables.
Results
A total of 196 patients were included during a one year 
period. 54.1% were male and 45.9% were women. The mean 
age of the total sample was 28 ± 7 years.  40.8% of the patients 
were married, and 37.8% had a remunerated job.
Regarding the clinical aspects of epilepsy: 35.7% of 
cases were classiﬁ  ed as cryptogenic (deﬁ  ned as epilepsy 
without an structural lesion, without family history, and 
without studies to determine a possible genetic syndrome); 
18.4% were genetic (those patients with a conﬁ  rmed genetic 
syndrome and family history); 14.8% were related to obstetric 
complications; 11.2% were secondary to medial temporal 
lobe sclerosis; 10.2% were posttraumatic; and 9.7% were 
associated with congenital malformations (structural lesions 
without family history and not related to obstetric compli-
cations, as cortical dysplasia or focal gliosis). The length 
of disease was variable, with a median of 17 years, range 
1–45. The mean age of onset of seizures was 11.3 years 
(SD 7.9 years). The mean frequency of seizures was 12.5 
(SD 27.95) events in the past year. Only 23.5% of patients 
had a good seizure control, deﬁ  ned for purposes of this 
study as no seizures in the past year; while poor seizure 
control was deﬁ  ned as one or more seizures in the past year. 
Patients with polytherapy were 71.9% of sample. The most 
commonly used drug was phenytoin (59.2%), followed by 
carbamazepine (55.1%), primidone (31.1%), valproic acid 
(26.5%), lamotrigine (6.6%), and others.
According to both scales (BDI and MADRS) 42.3% 
of the patients were considered depressed. The HAMA 
ratings revealed that 38.8% experienced signiﬁ  cant anxiety 
symptoms, as deﬁ  ned by a rating above 18 points. The 
symptoms most frequently reported as positive (items with 
a score different than 0) among all included patients, and Neuropsychiatric Disease and Treatment 2008:4(6) 1237
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among those diagnosed with clinically signiﬁ  cant anxiety 
are reported in Table 1.
There were no differences between anxious and 
nonanxious patients with epilepsy, regarding gender, marital 
status, or economical activity. Among the clinical variables, 
depression, posttraumatic epilepsy, educational degree, poly-
therapy, use of primidone, and inadequate seizure control 
were related to the presence of signiﬁ  cant anxiety symptoms 
in the bivariate analysis; but only use of primidone, depres-
sion, cryptogenic, and posttraumatic etiologies signiﬁ  cantly 
predicts anxiety among our patients after logistic regression 
as shown in Table 2. We did not ﬁ  nd association between 
duration of epilepsy, age of onset, and the frequency of 
partial complex seizures or temporal epilepsy with anxiety 
among our patients.
Discussion
In our study, nearly 40% of our patients had self-reported 
moderate or severe anxiety. This high frequency could be 
related to the clinical setting, since our institution is a refer-
ral center where the majority of patients have refractory 
epilepsy. However, socioeconomic factors related to lower 
quality of life, previously reported in Mexican patients 
(Alanis-Guevara et al 2005) could play a role in this high 
frequency of anxiety.
Among our patients, depression was the most important 
predictor of anxiety. The association between anxiety and 
depression (78% in our population) was very common, and 
has been reported in other studies (Cramer et al 2005). This 
is an important matter in the clinical practice, since depres-
sive-anxious patients are at increased risk for hospitalization, 
suicide attempt, a more chronic course, and impairment 
compared to patients with only depression (Zimmerman 
2006). The recognition of the comorbidity must be stressed, 
since it could modify the clinicians’ decision for therapy in 
these patients.
Temporal lobe epilepsy and some antiepileptic drugs, 
especially topiramate (Mula et al 2003) have been related 
with interictal anxiety. In our study, anxiety was not associ-
ated with temporal lobe epilepsy, and the only medication 
associated with anxiety among our patients was primidone, 
fact that could be related to their association with depres-
sion, described before (Lopez-Gomez et al 2005). However, 
the design of the study does not allow us to determine the 
inﬂ  uence of antiepileptic medication in the outcome of our 
study.
Another interesting fact was the association between 
cryptogenic and posttraumatic epilepsies the presence of 
anxiety in patients with cryptogenic epilepsy could be related 
both to psychological reactions from the uncertainty of the 
cause; and neurobiological factors described for the postcon-
cussion syndrome in the posttraumatic epilepsy.
In our patients, the most common isolated symptom of 
anxiety reported was the presence of fears, but symptoms 
Table 1 Frequency of reported anxiety symptoms in 196 patients with epilepsy
HAMA items All patients included 
(N = 196)
Patients with anxiety 
(N = 76)
Patients without anxiety 
(N = 120)
p
Anxious mood 158 (80.6%) 76 (100%) 82 (68.3%) 0.001
Tension 156 (79.6%) 76 (100%) 80 (66.7%) 0.001
Fears 177 (90.3%) 72 (94.7%) 105 (87.5%) 0.728
Insomnia 140 (71.4%) 73 (96.1%) 67 (55.8%) 0.001
Intellectual function 148 (75.5%) 72 (94.7%) 76 (63.3%) 0.001
Depressed mood 154 (78.6%) 76 (100%) 78 (65%) 0.001
Muscular complaints 150 (76.5%) 60 (78.9%) 90 (75%) 0.525
Sensory complaints 158 (80.6%) 66 (86.8%) 92 (76.7%) 0.079
Cardiovascular
 symptoms
83 (42.3%) 41 (53.9%) 42 (35%) 0.009
Respiratory symptoms 81 (41.3%) 38 (50%) 43 (35.8%) 0.054
Gastrointestinal
 symptoms
57 (29.1%) 19 (25%) 38 (31.7%) 0.317
Genitourinary
 symptoms
174 (88.8%) 74 (97.4%) 100 (83.3%) 0.002
Autonomic symptoms 116 (59.2%) 45 (59.2%) 71 (59.2%) 0.995
Anxious behavior 158 (80.6%) 76 (100%) 82 (68.3%) 0.001Neuropsychiatric Disease and Treatment 2008:4(6) 1238
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that differentiate between patients with and without anxiety 
were anxious mood, tension, insomnia, intellectual function, 
depressed mood, cardiovascular symptoms, genitourinary 
symptoms and anxious behavior. This ﬁ  nding suggests that 
the effect of somatic symptoms on the frequency of anxiety 
in patients with epilepsy is modest, something previously 
reported among other patients with complex physical illness 
and disability (Smallbrugge et al 2005). Since the fears item 
of the HAMA scale is evaluated according to the presence of 
fears to being left alone, of crowds and of strangers among 
others, we think that patients with epilepsy, due to their fear 
to have a seizure in different settings, with different people 
and for that to be discriminated, could be the main reason 
why this item was uninformative here.
Assessment of anxiety disorders in epilepsy is difﬁ  cult 
because anxiety symptoms such as fear are part of the seizure 
itself (Hughes et al 1993) and because of the overlap between 
depression and anxiety symptoms (Altshuler et al 1990). 
However, all health-related quality of life domains have been 
found to be signiﬁ  cantly worse with the presence of anxiety 
symptoms independently of the presence of depressive symp-
toms (Altshuler et al 1990; Cramer et al 2005). Further efforts 
must be performed in order to build up a speciﬁ  c instrument 
to diagnose anxiety in this population.
One major ﬂ  aw in our study is that cross-sectional design 
does not permit to establish the role of the psychosocial risk 
factors for anxiety in epilepsy which may include reactions 
to the unpredictable nature of epilepsy, restrictions in normal 
living such as driving and employment, lack of ﬁ  nancial 
security and the need to depend on family members. This can 
lead to low self-esteem, stigmatization and social rejection 
(Johnson et al 2004). Prospective studies must be performed 
in the future to determine the evolution of the anxiety among 
patients with epilepsy.
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